Midatech Pharma Plc (MTP) EPS Estimated At $-0.10

June 26, 2018 - By Michael Collier

Midatech Pharma Plc (NASDAQ:MTP) Logo

Analysts expect Midatech Pharma Plc (NASDAQ:MTP) to report $-0.10 EPS on July, 23. The stock decreased 1.24% or $0.0087 during the last trading session, reaching $0.6913. About 1,499 shares traded. Midatech Pharma Plc (NASDAQ:MTP) has declined 72.41% since June 26, 2017 and is downtrending. It has underperformed by 84.98% the S&P500.

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on the development and commercialization of oncology and other therapeutic products in the United Kingdom, Turkey, other European countries, and the United States. The company has market cap of $23.79 million. It offers Oravig, an orally dissolving buccal tablet for oral thrush and oropharyngeal candidiasis in adults; Gelclair, an oral rinse gel for the management and relief of pain arising from oral lesions of various etiologies; Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; and Soltamox, an oral liquid solution of tamoxifen citrate for the prevention of breast cancer. It currently has negative earnings. The firm also engages in the marketing of Ferralet 90, a prescription iron supplement for the treatment of anemias that are responsive to oral iron therapy; and Aquoral, an artificial saliva spray to provide relief from chemotherapy/radiation therapy.

More recent Midatech Pharma Plc (NASDAQ:MTP) news were published by: Benzinga.com which released: “36 Biggest Movers From Friday” on June 11, 2018. Also Globenewswire.com published the news titled: “Midatech Pharma US enrols first patient in Gelclair trial in stem cell transplant” on June 08, 2018. Benzinga.com‘s news article titled: “30 Stocks Moving In Friday’s Mid-Day Session” with publication date: June 08, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: